Acyclovir suppression dose

We use 200 mg oral acyclovir once a day for daily low-dose acyclovir suppressive therapy in our patients with genital herpes caused by HSV-2 who have six or more recur-rences per year. Thus, this study is designed to characterize the affect of long-term, low-dose acyclovir suppressive ther-apy on susceptibility to acyclovir and frequency of

The acyclovir dose when used as suppressive therapy is 400 mg Prophylactic acyclovir also has been used to prevent reactivation of herpes labialis following

receiving suppressive daily dosage acyclovir and the patients receiving of daily suppressive acyclovir therapy remains unre¬ solved. Although this

In another study by Dr. Serna-Ojeda, he and his colleagues treated pediatric patients with six months of oral acyclovir at a suppression dose level before proceeding with keratoplasty. They then continued the acyclovir at the suppression dose indefinitely.

Effect of Long-Term, Low-Dose Acyclovir Suppressive Therapy on Susceptibility to Acyclovir and Frequency of Acyclovir Resistance of Herpes Simplex Virus Type 2

We use acyclovir 400 mg three times daily as suppressive therapy. Doses for suppressive therapy are higher in pregnant compared with nonpregnant

first recurrence of symptoms in favor of suppressive dosing (P 0.0001). Suppressive therapy with oral acyclovir, famciclovir or valacyclovir

Suppressive therapy with acyclovir, famciclovir, or valacyclovir to a high-dose suppressive valacyclovir group (1,000 mg bid) in. ART

Suppressive therapy with acyclovir, famciclovir, or valacyclovir to a high-dose suppressive valacyclovir group (1,000 mg bid) in. ART